Sodium-Glucose Co-Transporter 2 inhibition prior to cardiac surgery and postoperative atrial fibrillation: a pilot randomised controlled trial

Phase 1

• Conditions: Atrial fibrillation; Cardiothoracic surgery; Cardiovascular - Other cardiovascular diseases; Surgery - Other surgery

• Registration Number: ACTRN12621000684820
• Lead Sponsor: Flinders University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-04
• Last Update Posted: 14 June 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Participants undergoing planned elective cardiac surgery (> 1 month prior to surgical date at time of enrolment)

Exclusion Criteria

Patients who are unable or unwilling to provide consent.
Patients who do not have access to a smartphone.
Patients who do not consent to study coordinator discussing their involvement with their GP.
Contraindications to SGLT2 commencement; patients already taking SGLT2 inhibitors, history of impaired kidney function (eGFR <45mL/min/1.73m2), Child –Pugh C cirrhosis, pregnancy, breastfeeding, symptomatic hypotension/ systolic blood pressure <100mmHg, type 1 diabetes mellitus, or previous SGLT2 intolerance or allergy, in line with current published contraindications to therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified